Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI

Sponsor
Soterix Medical (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05598931
Collaborator
Columbia University (Other)
10
1
19
0.5

Study Details

Study Description

Brief Summary

Healthy controls (HC) will be studied once to provide data needed to validate the virtual neuro-navigation system. All subjects will undergo a single MRI session and will then participate in an on-line neuro-navigation session in which various TMS coil positions will be recorded. The brain/head images will be provided to the programmer to permit development of the virtual neuro-navigation algorithm. Data from Yr1 will be used by the programmer as a training sample, and from Yr2 as a test sample.

Condition or Disease Intervention/Treatment Phase
  • Device: Transcranial Magnetic Stimulation

Detailed Description

HC subjects (n=10)/yr will be studied once to provide data needed to validate the virtual neuro-navigation system. All subjects will undergo a single Human Connectome Project compatible MRI session permitting application of both surface-based and more standard volumetric analyses. Subjects will then participate in an on-line neuro-navigation session in which TMS coil positions (in 10/20 coordinate space) will be recorded corresponding to the following targets: 1) hand-representation of motor strip; 2) 5-cm location; 3) 5.5 cm location; 4) MNI coordinates corresponding to the "Fitzgerald"4 and "Weigand"6 volumetric targets; 5) peak anti-correlated region (calculated from rsfcfMRI data alone); 6) center of our targeted parcel, calculated using surface-based approaches. The brain/head images will be provided to the programmer to permit development of the virtual neuro-navigation algorithm. Data from Yr1 will be used by the programmer as a training sample, and from Yr2 as a test sample. The Go/No-go criterion is an interclass correlation coefficient (ICC) of >.9 between scalp coordinates determined by on-line neuro-navigation and those determined virtually

Study Design

Study Type:
Observational
Anticipated Enrollment :
10 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI
Actual Study Start Date :
Jul 1, 2021
Anticipated Primary Completion Date :
Jan 31, 2023
Anticipated Study Completion Date :
Jan 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Healthy Controls

Subjects will undergo a single MRI session and will then participate in an on-line neuro-navigation session in which various TMS coil positions will be recorded. The brain/head images will be provided to the programmer to permit development of the virtual neuro-navigation algorithm. Data from Yr1 will be used by the programmer as a training sample, and from Yr2 as a test sample.

Device: Transcranial Magnetic Stimulation
Subjects will participate in an on-line neuro-navigation session in which 6 TMS coil positions will be recorded.

Outcome Measures

Primary Outcome Measures

  1. Brain Coordinates [Day 1]

    MRI based brain coordinates will be determined using newly developed neuronavigation software

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Non-depressed subjects
Exclusion Criteria:
  • Ever met criteria for a psychotic disorder (Sz, SzAff, Bipolar disorder); anorexia nervosa or bulimia nervosa within the last year

  • Unstable medical condition by history, physical exam or laboratory results

  • Contraindications to MRI (based on metal screening form)

  • Meets criteria for claustrophobia

  • Recent drug or alcohol use disorder with DSM-5 specifier of moderate or severe within 6 months, or mild within 2 months; lifetime history of IV drug use

  • A neurological or neuromuscular disorder;

  • Require medications for a general medical condition that contraindicate the TMS treatment

  • History of ketamine treatment within 6 mo

  • History of monoamine oxidase inhibitor (MAOI) within the past month

  • Lacks capacity to consent

  • Taking medications that increase the risk of seizures. For patients on permitted concomitant psychotropic agents (antidepressants, anticonvulsants, benzodiazepines, hypnotics, opiates, triiodothyronine (T3), modafinil, psychostimulants, buspirone, melatonin, omega-3 fatty acids, folate, lmethylfolate, s-adenosyl methionine, lithium) dosing must be stable for at least four weeks prior to study entry

Contacts and Locations

Locations

Site City State Country Postal Code
1 Columbia University Irving Medical Center New York New York United States 10032

Sponsors and Collaborators

  • Soterix Medical
  • Columbia University

Investigators

  • Principal Investigator: Marta Moreno-Ortega, PhD, Columbia University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Soterix Medical
ClinicalTrials.gov Identifier:
NCT05598931
Other Study ID Numbers:
  • SMICU061621B
First Posted:
Oct 28, 2022
Last Update Posted:
Oct 28, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 28, 2022